CPRX vs MDGL vs ARWR vs INVA vs ABBV

For growth investors, Arrowhead Pharmaceuticals, Inc.

(ARWR) is the stronger pick with 232. 6% revenue growth year-over-year, versus 8. 6% for AbbVie Inc. (ABBV). Innoviva, Inc. (INVA) offers the better valuation at 6. 9x trailing P/E (11. 9x forward), making it the more compelling value choice. Analysts rate Catalyst Pharmaceuticals, Inc. (CPRX) a "Buy" — based on 16 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Innoviva, Inc.

(INVA) is the cheapest at 6. 9x versus AbbVie Inc. at 85. 5x. On forward P/E, Innoviva, Inc. is actually cheaper at 11. 9x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Catalyst Pharmaceuticals, Inc. wins at 0. 88x versus Innoviva, Inc. 's 1. 15x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Catalyst Pharmaceuticals, Inc.

(CPRX) delivered a total return of +545. 2%, compared to +17. 4% for Arrowhead Pharmaceuticals, Inc. (ARWR). Over 10 years, the gap is even starker: CPRX returned +48. 0% versus INVA's +94. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Innoviva, Inc.

(INVA) is the lower-risk stock at 0. 13β versus Arrowhead Pharmaceuticals, Inc. 's 1. 81β — meaning ARWR is approximately 1337% more volatile than INVA relative to the S&P 500. On balance sheet safety, Catalyst Pharmaceuticals, Inc. (CPRX) carries a lower debt/equity ratio of 0% versus 73% for Arrowhead Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Arrowhead Pharmaceuticals, Inc.

(ARWR) is pulling ahead at 232. 6% versus 8. 6% for AbbVie Inc. (ABBV). On earnings-per-share growth, the picture is similar: Innoviva, Inc. grew EPS 816. 7% year-over-year, compared to -0. 8% for AbbVie Inc.. Over a 3-year CAGR, ARWR leads at 50. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Innoviva, Inc.

(INVA) is the more profitable company, earning 63. 8% net margin versus -30. 1% for Madrigal Pharmaceuticals, Inc. — meaning it keeps 63. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CPRX leads at 43. 8% versus -31. 3% for MDGL. At the gross margin level — before operating expenses — ARWR leads at 97. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Catalyst Pharmaceuticals, Inc. (CPRX) is the more undervalued stock at a PEG of 0. 88x versus Innoviva, Inc. 's 1. 15x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Innoviva, Inc. (INVA) trades at 11. 9x forward P/E versus 16. 6x for Catalyst Pharmaceuticals, Inc. — 4. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for INVA: 65. 2% to $37. 67.

In this comparison, ABBV (3.

2% yield) pays a dividend. CPRX, MDGL, ARWR, INVA do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, AbbVie Inc.

(ABBV) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 34), 3. 2% yield, +295. 5% 10Y return). Arrowhead Pharmaceuticals, Inc. (ARWR) carries a higher beta of 1. 81 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ABBV: +295. 5%, ARWR: +1253%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: CPRX is a small-cap high-growth stock; MDGL is a mid-cap high-growth stock; ARWR is a mid-cap high-growth stock; INVA is a small-cap high-growth stock; ABBV is a large-cap income-oriented stock. ABBV pays a dividend while CPRX, MDGL, ARWR, INVA do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.